Marshall Wace
ONSIZ

Marshall Wace’s Oncobiologics, Inc. Series B Warrant ONSIZ Stock Holding History

Marshall Wace’s Portfolio ONSIZ Stock Details ONSIZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-125,100
Closed -$99K – 934
2016
Q4 		$99K Hold
125,100
– – ﹤0.01% 939
2016
Q3 		$150K Hold
125,100
– – ﹤0.01% 903
2016
Q2 		$56K Buy
+125,100
New +$65.8K ﹤0.01% 963

Other funds holding ONSIZ

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
MIM
Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Marshall Wace's ONSIZ Position: Q1 2017 in Review

Marshall Wace sold out of Oncobiologics, Inc. Series B Warrant (ONSIZ) in Q1 2017, closing a stake of 125,100 shares — an estimated $99K sold.

Marshall Wace first reported a position in ONSIZ in Q2 2016 and held it in 3 quarters. The position peaked at $150K in Q3 2016. 10 funds tracked by Wall St. Rank hold ONSIZ as of Q1 2017.

  • Marshall Wace reported no remaining Oncobiologics, Inc. Series B Warrant position as of Q1 2017 after selling out during the quarter.
  • Marshall Wace sold 125,100 Oncobiologics, Inc. Series B Warrant shares in Q1 2017, an estimated $99K.
  • Marshall Wace first reported a position in Oncobiologics, Inc. Series B Warrant in Q2 2016 and held it in 3 quarters.
  • Marshall Wace's Oncobiologics, Inc. Series B Warrant position peaked at $150K in Q3 2016.
  • 10 funds tracked by Wall St. Rank held Oncobiologics, Inc. Series B Warrant as of Q1 2017.

Based on Marshall Wace's 13F filing for Q1 2017, filed 12 May 2017.